Article Details

Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early ...

Retrieved on: 2022-08-04 15:51:50

Tags for this article:

Click the tags to see associated articles and topics

Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early .... View article details on HISWAI: https://www.precisiononcologynews.com/regulatory-news-fda-approvals/merck-astrazeneca-net-european-approval-adjuvant-lynparza-brca

Excerpt

NEW YORK – The European Commission on Thursday approved AstraZeneca and Merck's PARP inhibitor Lynparza (olaparib) as adjuvant treatment, ...

Article found on: www.precisiononcologynews.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up